Meeder Asset Management Inc Mersana Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$16.84 - $27.59 $164,291 - $269,168	-9,756 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$5.24 - $23.4 $22,264 - $99,426	4,249 Added 77.16%	9,756 $228,000
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $18,138 - $38,168	4,113 Added 295.05%	5,507 $32,000
Q4 2019 Feb 13, 2020	SELL	$1.45 - $6.73 $880 - $4,085	-607 Reduced 30.33%	1,394 $8,000
Q3 2019 Oct 17, 2019	BUY	$1.54 - $4.2 $2,584 - $7,047	1,678 Added 519.5%	2,001 $3,000
Q2 2019 Aug 05, 2019	BUY	$3.84 - $6.4 $134 - $224	35 Added 12.15%	323 $1,000
Q1 2019 Apr 16, 2019	BUY	$3.51 - $7.3 $1,010 - $2,102	288 New	288 $2,000
Q1 2018 May 03, 2018	SELL	$13.56 - $18.48 $298 - $406	-22 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$14.95 - $19.9 $328 - $437	22	22 $0

136

101M

77.2K

453K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $51.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.